Gene · 54583
Papers3,727
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 3,727
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A novel germline hyperactivating JAK2 mutation L604F. | Ann Hematol | 2023 | 37639050 | PubTator, text mining | PubMed |
| Deciphering the Functional Status of Breast Cancers through the Analysis of Their Extracellular Vesicles. | Int J Mol Sci | 2023 | 37629204 | PubTator, text mining | PubMed |
| Different RONS Generation in MTC-SK and NSCL Cells Lead to Varying Antitumoral Effects of Alpha-Ketoglutarate + 5-HMF. | Curr Issues Mol Biol | 2023 | 37623229 | PubTator, text mining | PubMed |
| Physiological oxygen conditions enhance the angiogenic properties of extracellular vesicles from human mesenchymal stem cells. | Stem Cell Res Ther | 2023 | 37612731 | PubTator, text mining | PubMed |
| Exosomal miRNA-mediated intercellular communications and immunomodulatory effects in tumor microenvironments. | J Biomed Sci | 2023 | 37605155 | PubTator, text mining | PubMed |
| Crosstalk between hypoxic cellular micro-environment and the immune system: a potential therapeutic target for infectious diseases. | Front Immunol | 2023 | 37600803 | PubTator, text mining | PubMed |
| Ferroptosis and EMT: key targets for combating cancer progression and therapy resistance. | Cell Mol Life Sci | 2023 | 37598126 | PubTator, text mining | PubMed |
| Radiation combined with ultrasound and microbubbles: A potential novel strategy for cancer treatment. | Z Med Phys | 2023 | 37586962 | PubTator, text mining | PubMed |
| Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1α. | Mol Oncol | 2023 | 37584455 | PubTator, text mining | PubMed |
| An integrated organoid omics map extends modeling potential of kidney disease. | Nat Commun | 2023 | 37580326 | PubTator, text mining | PubMed |
| Comparative analysis of N-terminal cysteine dioxygenation and prolyl-hydroxylation as oxygen-sensing pathways in mammalian cells. | J Biol Chem | 2023 | 37572852 | PubTator, text mining | PubMed |
| Interruption of p53-MDM2 Interaction by Nutlin-3a in Human Lymphoma Cell Models Initiates a Cell-Dependent Global Effect on Transcriptome and Proteome Level. | Cancers (Basel) | 2023 | 37568720 | PubTator, text mining | PubMed |
| Case Report: Aggressive neural crest tumors in a child with familial von Hippel Lindau syndrome associated with a germline VHL mutation (c.414A>G) and a novel KIF1B gene mutation. | Front Endocrinol (Lausanne) | 2023 | 37564981 | PubTator, text mining | PubMed |
| Unveiling the veil of lactate in tumor-associated macrophages: a successful strategy for immunometabolic therapy. | Front Immunol | 2023 | 37564659 | PubTator, text mining | PubMed |
| Anticancer therapeutic effect of ginsenosides through mediating reactive oxygen species. | Front Pharmacol | 2023 | 37564184 | PubTator, text mining | PubMed |
| Exosomal non-coding RNAs in angiogenesis: Functions, mechanisms and potential clinical applications. | Heliyon | 2023 | 37560684 | PubTator, text mining | PubMed |
| Cellular metabolism hijacked by viruses for immunoevasion: potential antiviral targets. | Front Immunol | 2023 | 37559723 | PubTator, text mining | PubMed |
| REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial. | Mol Cancer | 2023 | 37559050 | PubTator, text mining | PubMed |
| Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma. | J Immunother Cancer | 2023 | 37553182 | PubTator, text mining | PubMed |
| Corrigendum to "Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia" [Eur. J. Med. Chem. 238 (2022) 114479]. | Eur J Med Chem | 2023 | 37550158 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/54583/papers?page=18